BioSpace News Archive

Policy

Statement from the Chief Public Health Officer of Canada on September 27, 2020

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

September 27, 2020
·
2 min read
Deals

InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures

InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds.

September 27, 2020
·
4 min read
Deals

Qiming’s Portfolio Company Zai Lab Lists on Main Board of HKEX

Qiming’s portfolio company Zai Lab, an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited

September 27, 2020
·
3 min read
Policy

TYVYT® in Combination with BYVASDA® ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced the results of a Phase 3, open label, randomized study in China.

September 27, 2020
·
9 min read
Drug Development

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, announced APL-106 has received Investigational New Drug approval from the China National Medical Products Administration Center for Drug Evaluation.

September 27, 2020
·
3 min read